A Phase 2 Study of Kevetrin (Thioureidobutyronitrile) in Subjects With Platinum-Resistant/Refractory Ovarian Cancer
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Thioureidobutyronitrile (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Innovation Pharmaceuticals
- 08 Feb 2018 Status changed from recruiting to completed, according to an Innovation Pharmaceuticals media release.
- 27 Dec 2017 Preliminary data from the first patients in this trial presented in an Innovation Pharmaceuticals media release.
- 14 Sep 2017 According to an iPharma media release, the company expects initial primary results in 4th quarter 2017.